SenzaGen AB recruites Anki Malmborg Hager as CEO

SenzaGen AB, a diagnostic spin-off company from Lund University, announces the that Dr Anki Malmborg Hager will take the position as CEO for the company.

SenzaGen AB is a diagnostic company working to replace animal testing. There is an increasing international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen offers such a choice and its products are in vitro based tests accurately determining the sensitization ability of substances.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University conducted by Assoc. Prof. Malin Lindstedt and coworkers.

“The 2013 ban on animal testing in the cosmetic industry provides Senzagen with an optimal opportunity to launch many years of research into society and enter a commercial phase of our products,” says Assoc. Prof. Malin Lindstedt.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers including other routes of exposure.

Based on the demand from the market the company is now gearing up its commercial operations and the first step is to recruit an experienced CEO.

“We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen.

Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the University. She held the position as Investment Director in Lund University Bioscience AB between 2009 and 2011 as well as management positions in eg. Alligator Bioscience AB, XImmune AB (CEO), Cantargia AB (CEO), and Diaprost AB (CEO).

“I am very pleased to have been offered this opportunity” says Anki Malmborg Hager. “The underlying research in SenzaGen is world class and the market window of opportunity is timely and very exciting. I am looking forward to joining the SenzaGen team and to lead the next steps in the commercialization of many years of first-class research”.


For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB

carl.borrebaeck@immun.lth.se

+46 708 218330

About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

Subscribe

Media

Media

Documents & Links